Assessing the Generalizability of Machine Learning Models for Chronic Kidney Disease Prediction Using Cross-Dataset Validation

Why It Matters

The findings underscore that external, cross‑dataset validation is essential for reliable CKD risk models, influencing how hospitals and insurers might deploy AI‑driven screening tools.

Key Takeaways

• Logistic Regression hit 98% accuracy on both datasets
• Random Forest excelled when trained on Dataset B
• Hemoglobin and urine gravity top predictive features
• External validation critical for healthcare ML reliability
• Model stability confirmed across 30 random seeds

Pulse Analysis

Early detection of chronic kidney disease can dramatically reduce the need for dialysis and lower cardiovascular risk, yet many patients remain undiagnosed until advanced stages. Machine learning offers a pathway to flag high‑risk individuals using routine lab values, but the clinical utility of any algorithm hinges on its ability to generalize beyond the data it was trained on. This study’s cross‑dataset approach—training on one cohort and testing on another—mirrors real‑world deployment where patient populations differ in demographics, measurement protocols, and disease prevalence.

The comparative results reveal nuanced trade‑offs among classic and ensemble models. Logistic Regression delivered consistently high accuracy (≈98%) and virtually no performance variance across 30 random seeds, suggesting robustness to data perturbations. Random Forest, while slightly less stable, achieved the top accuracy (97.75%) when the training set was the smaller Dataset B, indicating its capacity to capture complex interactions when data quality is high. Feature importance analysis aligned with established CKD pathology, reinforcing that a modest set of variables—hemoglobin, urine specific gravity, albumin, serum creatinine, hypertension, diabetes—can drive reliable predictions without extensive electronic health record mining.

For health systems and payers, the study highlights two actionable insights. First, model selection should prioritize stability and interpretability, especially when regulatory scrutiny demands transparent risk scores. Second, rigorous external validation must become a standard checkpoint before integrating AI tools into clinical workflows, mitigating the risk of overfitting to a single institution’s data. Future research will likely explore larger, multi‑regional datasets and incorporate longitudinal trends to further refine CKD risk stratification, paving the way for proactive, data‑driven patient care.